Atorvastatin delays progression of pancreatic lesions to carcinoma by regulating PI3/AKT signaling in p48 Cre/+ LSL-Kras G12D/+ mice

International Journal of Cancer

Volumn 131, Issue 8, 2012, Pages 1951-1962

  Mohammed, Altaf ^a   Qian, Li ^a   Janakiram, Naveena B ^a   Lightfoot, Stan ^a   Steele, Vernon E ^b   Rao, Chinthalapally V ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

atorvastatin; p48 Cre + LSL Kras G12D + mice; pancreatic cancer; PI3 AKT

Indexed keywords

ATORVASTATIN; BETA CATENIN; CAVEOLIN 1; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLINE; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P48; PURINERGIC P2X7 RECEPTOR; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SURVIVIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER INCIDENCE; CANCER INHIBITION; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG DETERMINATION; DRUG EFFICACY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME REGULATION; HISTOPATHOLOGY; MALE; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS ADENOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, PANCREATIC DUCTAL; CELL PROLIFERATION; CYTOKINES; DISEASE PROGRESSION; FLUORESCENT ANTIBODY TECHNIQUE; HEPTANOIC ACIDS; HUMANS; IMMUNOENZYME TECHNIQUES; INTEGRASES; INTERFERON-STIMULATED GENE FACTOR 3, GAMMA SUBUNIT; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION; PANCREATIC NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS P21(RAS); PYRROLES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 84865315753     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27456     Document Type: Article

References (51)

1. American Cancer Society. Cancer facts and figures. Atlanta (GA): American Cancer Society, 2011.
2. Eckel F, Schneider G, Schmid RM,. Pancreatic cancer: a review of recent advances. Expert Opin Investig Drugs 2006; 15: 1395-410. (Pubitemid 44615288)
3. Hruban RH, Adsay NV, Albores-Saavedra J, Anver MR, Biankin AV, Boivin GP, Furth EE, Furukawa T, Klein A, Klimstra DS, Kloppel G, Lauwers GY, et al. Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. Cancer Res 2006; 66: 95-106. (Pubitemid 43166014)
4. Sakorafas GH, Tsiotou AG, Tsiotos GG,. Molecular biology of pancreatic cancer; oncogenes, tumor suppressor genes, growth factors, and their receptors from a clinical perspective. Cancer Treatment Rev 2000; 26: 29-52. (Pubitemid 30102799)
5. Ren YX, Xu GM, Li ZS, Song YG,. Detection of point mutation in K-ras oncogene at codon 12 in pancreatic diseases. World J Gastroenterol 2004; 10: 881-4.
6. Mohammed A, Janakiram NB, Li Q, Madka V, Ely M, Lightfoot S, Crawford H, Steele VE, Rao CV,. EGFR inhibitor gefitinib prevents progression of pancreatic lesions to carcinoma in a conditional LSL-K-rasG12D transgenic mice model. Cancer Prev Res 2010; 3: 1417-26.
7. Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, Ross S, Conrads TP, Veenstra TD, Hitt BA, Kawaguchi Y, Johann D, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003; 4: 437-50. (Pubitemid 38050041)
8. Demierre MF, Higgins PDR, Stephen B, Gruber, Hawk E, Lippman SM,. Statins and cancer prevention. Nat Rev Cancer 2005; 5: 930-42. (Pubitemid 41766782)
9. Kusama T, Mukai M, Iwasaki T, Tatsuta M, Matsumoto Y, Akedo H, Inoue M, Nakamura H,. 3-Hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. Gastroenterology 2002; 122: 308-17. (Pubitemid 34116983)
10. Kaminski R, Kozar K, Kopec M, Basak G, Skierski JS, Koronkiewicz M, Jakobisiak M, GolAb J,. Discussion on 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. Gastroenterology 2002; 123: 1747-48. (Pubitemid 35231674)
11. Platz EA, Leitzmann MF, Visvanathan K, Rimm EB, Stampfer MJ, Willett WC, Giovannucci E,. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 2006; 98: 1819-25. (Pubitemid 46017933)
12. Khurana V, Sheth A, Caldito G, Barkin JS,. Statins reduce the risk of pancreatic cancer in humans: a case-control study of half a million veterans. Pancreas 2007; 34: 260-5. (Pubitemid 46294804)
13. Kawata S, Nagase T, Yamasaki E, Ishiguro H, Matsuzawa Y,. Modulation of the mevalonate pathway and cell growth by pravastatin and dlimonene in a human hepatoma cell line (Hep G2). Br J Cancer 1994; 69: 1015-20. (Pubitemid 24161851)
14. Feleszko W, Jakobisiak M,. Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clin Cancer Res 2000; 6: 1198-9.
15. Sumi S, Beauchamp RD, Townsend CM, Uchida T, Murakami M, Rajaraman S, Ishizuka J, Thompson JC,. Inhibition of pancreatic adenocarcinoma cell growth by lovastatin. Gastroenterology 1992; 103: 982-9.
16. Mikulski SM, Viera A, Darzynkiewicz Z, Shogen K,. Synergism between a novel amphibian oocyte ribonuclease and lovastatin in inducing cytostatic and cytotoxic effects in human lung and pancreatic carcinoma cell lines. Br J Cancer 1992; 66: 304-10.
17. Kusama T, Mukai M, Iwasaki T, Tatsuta M, Matsumoto Y, Akedo H, Nakamura H,. Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3- hydroxy-3-methylglutaryl- coenzyme a reductase inhibitors. Cancer Res 2001; 61: 4885-91. (Pubitemid 32691906)
18. Swamy MV, Patlolla JM, Steele VE, Kopelovich L, Reddy BS, Rao CV,. Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice. Cancer Res 2006; 66: 7370-7. (Pubitemid 44197721)
19. Issat T, Nowis D, Legat M, Makowski M, Klejman MP, Urbanski J, Skierski J, Koronkiewicz M, Stoklosa T, Brezezinska A, Bil J, Gietka J, et al. Potentiated antitumor effects of the combination treatment with statins and pamidronate in vitro and in vivo. Int J Oncol 2007; 30: 1413-25.
20. Yao CJ, Lai GM, Chan CF, Cheng AL, Yang YY, Chuang SE,. Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazone. Int J Cancer 2006; 118: 773-9.
21. Bocci G, Fioravanti A, Orlandi P, Bernardini N, Collecchi P, Del Tacca M, Danesi R,. Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells. Br J Cancer 2005; 93: 319-30. (Pubitemid 43080034)
22. Mistafa O, Stenius U,. Statins inhibit AKT/PKB signaling via P2X7 receptor in pancreatic cancer cells. Biochem Pharmacol 2009; 78: 15-26.
23. Gbelcov H, Len M, Zelenka J, Knejzlik Z, DvorË̃kov G, Zadinov M, Pouckova P, Kudla M, Balaz P, Ruml T, Vitek L,. Differences in antitumor effects of various statins on human pancreatic cancer. Int J Cancer 2008; 122: 1214-21. (Pubitemid 351287219)
24. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA,. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 2006; 20: 18-49.
25. Krasilnikov MA,. Phosphatidylinositol-3 kinase dependent pathways: the role in control of cell growth, survival, and malignant transformation. Biochemistry 2000; 65: 59-67.
26. Wong WW, Dimitroulakos J, Minden MD, Penn LZ,. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 2002; 16: 508-19. (Pubitemid 34460459)
27. Kusama T, Mukai M, Ayaki M, Imamura F, Tatsuta M, Matsumoto Y, Nakamura H, Inoue M,. Inhibition of lysophosphatidic acid-induced RhoA activation and tumor cell invasion by 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Int J Oncol 2003; 23: 1173-78.
28. Paragh G, Kertai P, Kovacs P, Paragh G, Jr, Fulop P, Foris G,. HMG CoA reductase inhibitor fluvastatin arrests the development of implanted hepatocarcinoma in rats. Anticancer Res 2003; 23: 3949-54. (Pubitemid 37474348)
29. Denoyelle C, Vasse M, Korner M, Mishal Z, Ganne F, Vannier JP, Soria J, Soria C,. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study. Carcinogenesis 2001; 22: 1139-48. (Pubitemid 32737327)
30. Chan KK, Oza AM, Siu LL,. The statins as anticancer agents. Clin Cancer Res 2003; 9: 10-19. (Pubitemid 36109711)
31. Wong WW, Tan MM, Xia Z, Dimitroulakos J, Minden MD, Penn LZ,. Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin. Clin Cancer Res 2001; 7: 2067-75. (Pubitemid 32994846)
32. Horiguchi A, Sumitomo M, Asakuma J, Asano T, Asano T, Hayakawa M,. 3-Hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor, fluvastatin, as a novel agent for prophylaxis of renal cancer metastasis. Clin Cancer Res 2004; 10: 86-55.
33. Kawata S, Yamasaki E, Nagase T, Inui Y, Ito N, Matsuda Y, Inada M, Tamura S, Noda S, Imai Y, Matsuzawa Y,. Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer 2001; 84: 886-91. (Pubitemid 32385829)
34. Páá járvi G, Roudier E, Crisby M, Hõgberg J, Stenius U,. HMG-CoA reductase inhibitors, statins, induce phosphorylation of Mdm2 and attenuate the p53 response to DNA damage. FASEB J 2005; 19: 476-8. (Pubitemid 40316555)
35. Roudier E, Mistafa O, Stenius U,. Statins induce mammalian target of rapamycin (mTOR)-mediated inhibition of Akt signaling and sensitize p53-deficient cells to cytostatic drugs. Mol Cancer Ther 2006; 5: 2706-15. (Pubitemid 44848997)
36. Ng SSW, Tsao MS, Chow S, Hedley DW,. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res 2000; 60: 5451-5.
37. Pedersen TR, Wilhelmsen L, Faergeman O, Strandberg TE, Thorgeirsson G, Troedsson L, Kristianson J, Berg K, Cook TJ, Haghfelt T, Kjekshus J, Miettinen T, et al. Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering. Am J Cardiol 2000; 86: 257-62. (Pubitemid 30462217)
38. Blais L, Desgagne A, LeLorier J,. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med 2000; 160: 2363-8.
39. Funahashi H, Satake M, Dawson D, Huynh NA, Reber HA, Hines OJ, Eibl G,. Delayed progression of pancreatic intraepithelial neoplasia in a conditional KrasG12D/+ mouse model by a selective cyclooxygenase-2 inhibitor. Cancer Res 2007; 67: 7068-71. (Pubitemid 47206534)
40. Fendrich V, Chen NM, Neef M, Waldmann J, Buchholz M, Feldmann G, Slater EP, Maitra A, Bartsch DK,. The angiotensin-1-converting enzyme inhibitor enalapril and aspirin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer. Gut 2010; 59: 630-37.
41. Bai H, Li H, Zhang W, Matkowskyj KA, Liao J, Srivastava SK, Yang GY,. Inhibition of chronic pancreatitis and pancreatic intraepithelial neoplasia (PanIN) by capsaicin in LSL-KrasG12D/Pdx1-Cre mice. Carcinogenesis 2011; 32: 1689-96.
42. Hehlgans S, Eke I, Haase M, Baretton G, Cordes N,. Caveolin-1 mediated radioresistance of 3D grown pancreatic cancer cells. Radiother Oncol 2009; 92: 363-70.
43. Guruswamy S, Rao CV,. Synergistic effects of lovastatin and celecoxib on caveolin-1 and its downstream signaling molecules: implications for colon cancer prevention. Int J Oncol 2009; 35: 1037-43.
44. Suzuoki M, Miyamoto M, Kato K, Hiraoka K, Oshikiri T, Nakakubo Y, Fukunaga A, Shichinohe T, Sginohara T, Itoh T, Kondo S, Katoh H,. Impact of caveolin-1 expression on prognosis of pancreatic ductal adenocarcinoma. Br J Cancer 2002; 87: 1140-44. (Pubitemid 35418110)
45. Heeneman S, Donners MM, Bai L, Daemen MJ,. Drug-induced immunomodulation to affect the development and progression of atherosclerosis: a new opportunity? Expert Rev Cardiovas Ther 2007; 5: 345-64. (Pubitemid 46488147)
46. Wassmann S, Laufs U, Muller K, Konkol C, Ahlbory K, Baumer AT, Linz W, Bohm M, Nickenig G,. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 2002; 22: 300-5. (Pubitemid 34127043)
47. Kunzli BM, Berberat PO, Giese T, Csizmadia E, Kaczmarek E, Baker C, Halaceli I, Buchler MW, Friess H, Robson SC,. Upregulation of CD39/NTPDases and P2 receptors in human pancreatic disease. Am J Gastrointest Liver Physiol 2007; 292: 223-30.
48. Otsuki M,. Chronic pancreatitis in Japan: epidemiology, prognosis, diagnostic criteria, and future problems. J Gastroenterol 2003; 38: 315-26. (Pubitemid 36626266)
49. Maisonnneuve P, Lowenfels AB,. Chronic pancreatitis and pancreatic cancer. Dig Dis 2002; 20: 32-37.
50. Shimizu YM, Shirakami Y, Sakai H, Kubota M, Hata K, Hirose Y, Tsurumi H, Tanaka T, Moriwaki H,. Pitavastatin inhibits azoxymethane-induced colonic preneoplastic lesions in C57BL/KsJ-db/db obese mice. Cancer Sci 2010; 101: 1701-07.
51. Gabitass RF, Annels NE, Stocken DD, Pandha HA, Middleton GW,. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother 2011; 60: 1419-30.